First Targeted Treatment for Relapsed or Refractory AML with IDH1 Mutation
- FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation. U.S. Food & Drug Administration. Available at https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm614115.htm. Accessed 7/23/18.
- Tibsovo prescribing information. Available at https://www.tibsovopro.com/pdf/prescribinginformation.pdf. Accessed 7/23/18.
- Sagonowsky E. Agios wins FDA nod for targeted AML drug Tibsovo. Fierce Pharma. Available at https://www.fiercepharma.com/pharma/agios-wins-fda-nod-for-targeted-aml-drug-tibsovo. Accessed 7/23/18.
- About IDH mutations in cancer. Agios Pharmaceuticals. Available at http://www.agios.com/patients-caregivers/idh-mutations/. Accessed 7/23/18.